Abstract PS4-02-12: Combination of CDK4/6 and EZH2 Inhibitors Enhances Anti-Tumor Immunity in Triple-Negative Breast Cancer via the MAVS-TBK1-STAT1 Signaling Pathway and Synergizes with Anti-PD-1 Therapy